INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34801, 32403, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34802, 13907, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34803, 20565, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34804, 20566, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34805, 30662, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34806, 32403, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34807, 13907, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34808, 20565, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34809, 20566, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34810, 30662, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34811, 32403, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34812, 13907, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34813, 20565, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34814, 20566, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34815, 30662, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34816, 32403, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34817, 13907, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34818, 20565, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34819, 20566, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34820, 30662, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34821, 32403, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34822, 13907, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34823, 20565, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34824, 20566, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34825, 30662, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34826, 32403, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34827, 13907, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34828, 20565, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34829, 20566, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34830, 30662, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34831, 32403, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34832, 3595, 'Calcium acetate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34833, 7723, 'Calcium acetate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34834, 15668, 'Calcium acetate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34835, 3595, 'Calcium acetate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34836, 7723, 'Calcium acetate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34837, 15668, 'Calcium acetate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34838, 3595, 'Calcium acetate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34839, 7723, 'Calcium acetate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34840, 15668, 'Calcium acetate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34841, 3595, 'Calcium acetate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34842, 7723, 'Calcium acetate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34843, 15668, 'Calcium acetate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34844, 3595, 'Calcium acetate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34845, 7723, 'Calcium acetate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34846, 15668, 'Calcium acetate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34847, 1872, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34848, 1876, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34849, 1879, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34850, 1906, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34851, 1947, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34852, 3939, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34853, 4042, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34854, 8090, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34855, 10403, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34856, 11625, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34857, 13595, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34858, 13710, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34859, 15419, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34860, 15682, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34861, 15725, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34862, 15726, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34863, 21356, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34864, 21365, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34865, 21833, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34866, 22182, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34867, 24198, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34868, 25869, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34869, 26187, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34870, 27022, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34871, 30248, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34872, 1872, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34873, 1876, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34874, 1879, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34875, 1906, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34876, 1947, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34877, 3939, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34878, 4042, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34879, 8090, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34880, 10403, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34881, 11625, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34882, 13595, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34883, 13710, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34884, 15419, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34885, 15682, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34886, 15725, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34887, 15726, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34888, 21356, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34889, 21365, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34890, 21833, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34891, 22182, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34892, 24198, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34893, 25869, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34894, 26187, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34895, 27022, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34896, 30248, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34897, 1872, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34898, 1876, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34899, 1879, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34900, 1906, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
